0001127602-20-006488.txt : 20200219
0001127602-20-006488.hdr.sgml : 20200219
20200219165725
ACCESSION NUMBER: 0001127602-20-006488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200214
FILED AS OF DATE: 20200219
DATE AS OF CHANGE: 20200219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STAAB THOMAS R II
CENTRAL INDEX KEY: 0001230708
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23186
FILM NUMBER: 20630754
MAIL ADDRESS:
STREET 1: C/O INSPIRE PHARMACEUTICALS, INC.
STREET 2: 4222 EMPEROR BLVD., SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000882796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 621413174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: 919-859-1302
MAIL ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-02-14
0000882796
BIOCRYST PHARMACEUTICALS INC
BCRX
0001230708
STAAB THOMAS R II
4505 EMPEROR BLVD.
SUITE 200
DURHAM
NC
27703
1
Senior Vice President and CFO
Emp. Stock Option (Right to Buy)
11.13
2020-02-14
4
A
0
31500
0
A
2020-02-14
2024-12-22
Common Stock
31500
31500
D
On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested.
/s/ Alane P. Barnes, by power of attorney
2020-02-19